Therapy for Patients With Non–Small Cell Lung Cancer in the Absence of Genomic Mutations

Luis L. Paz-Ares, MD


October 30, 2020

Worldwide, lung cancer is the leading cause of cancer death. Therapeutic options for non–small cell lung cancer (NSCLC) have changed significantly in recent years because of the evolving recognition of genetic abnormalities and the development of targeted therapies for these mutations.

Many NSCLC patients, however, present without targetable mutations.

In this ReCAP, Dr Luis L. Paz-Ares, of University Hospital, Madrid, Spain, reflects on first- and second-line treatment strategies for patients without apparent targetable genetic alterations, using immunotherapy as a single agent or in combination with chemotherapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.